German diagnostics company Protagen said this week that it has received a Japanese patent for a method of identifying and selecting clones based on its UNIclone technology platform.
The UNIclone platform, which Protagen has licensed from Berlin's Max-Planck Institute, consists of libraries of human recombinant proteins representing more than 10,000 human genes. It is designed for use with the company's UNIarray companion diagnostic and UNIchip antibody profiling platform.
The company also possesses a European patent for the technology.
This June, Protagen signed a cooperation contract with Bayer Schering Pharma AG for the discovery of novel biomarkers in endometriosis using its UNIarray device, which uses proteins generated by the UNIclone platform (PM 06/11/2010).
In July it announced a partnership with Mikrogen to use the UNIarray platform for the discovery of autoantibody signatures associated with infectious diseases (PM 07/09/2010).
Last August the company received €3.7 million ($5.3 million) in funding to expand its work developing biomarkers for diseases including multiple sclerosis and prostate cancer.